CBIOCrescent Biopharma, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+13% of shares).
Rangebound, no clear trend. Price is −19% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, about a week of normal trading to cover.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CBIO is trading
Crescent Biopharma, Inc. is +1.1% over the past year while the S&P 500 is +16%: 15 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −19%
vs 200-day average · a clear downtrend
- RSI (14)
- 42
RSI (14) · neutral
- Below its 52-week high
- 52%
Below its 52-week high
Details›
- Last close2026-10-23
- $12.87
- 1 monthS&P 500 −0.94%
- −9.6%
- 1 yearS&P 500 +16%
- +1.1%
- 5 yearsS&P 500 +86%
- −106%
- vs 50-day average$15.98
- −19%
- 52-week high
- $26.98
- 52-week low
- $8.94
- Annualised volatility
- 157%
| Year | Return |
|---|---|
| 2026 (year to date) | +8.5% |
| 2025 | −53% |
| 2024 | −89% |
| 2023 | −15% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 4 | 3 of 4 | +5.2% |
| Feb | 4 | 1 of 4 | −6.2% |
| Mar | 4 | 2 of 4 | +3.8% |
| Apr | 4 | 3 of 4 | +3.0% |
| May | 4 | 1 of 4 | −19% |
| Jun | 4 | 1 of 4 | −9.7% |
| Jul | 4 | 0 of 4 | −17% |
| Aug | 4 | 2 of 4 | +2.5% |
| Sep | 4 | 0 of 4 | −10% |
| Oct | 5 | 3 of 5 | +29% |
| Nov | 4 | 3 of 4 | +63% |
| Dec | 4 | 2 of 4 | +8.6% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.